NSAID-induced  	NSAID-induced  	 FW	B-NP
urticaria 	urticaria 	 FW	I-NP
/ 	/ 	 FW	I-NP
angioedema  	angioedema  	 FW	I-NP
does  	does  	 VBZ	O
not  	not  	 RB	O
evolve  	evolve  	 VB	O
into  	into  	 IN	O
chronic  	chronic  	 JJ	B-NP
urticaria 	urticaria 	 NN	I-NP
:  	:  	 :	O
a  	a  	 DT	O
12-year  	12-year  	 JJ	O
follow-up  	follow-up  	 JJ	B-NP
study  	study  	 NN	I-NP
Nonsteroidal  	Nonsteroidal  	 NNP	I-NP
anti-inflammatory  	anti-inflammatory  	 JJ	I-NP
drugs  	drugs  	 NNS	I-NP
( 	( 	 -LRB-	O
NSAIDs 	NSAIDs 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
the  	the  	 DT	O
most  	most  	 RBS	O
frequent  	frequent  	 JJ	O
medicaments  	medicaments  	 NNS	O
involved  	involved  	 VBN	O
in  	in  	 IN	O
drug  	drug  	 NN	B-NP
hypersensitivity  	hypersensitivity  	 NN	I-NP
reactions 	reactions 	 NNS	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
NSAID-induced  	NSAID-induced  	 FW	B-NP
urticaria 	urticaria 	 FW	I-NP
/ 	/ 	 FW	I-NP
angioedema  	angioedema  	 FW	I-NP
( 	( 	 -LRB-	O
NIUA 	NIUA 	 NNP	B-NP
)  	)  	 -RRB-	O
being  	being  	 VBG	O
the  	the  	 DT	O
most  	most  	 RBS	O
frequent  	frequent  	 JJ	O
clinical  	clinical  	 JJ	B-NP
entity 	entity 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
natural  	natural  	 JJ	O
evolution  	evolution  	 NN	B-NP
of  	of  	 IN	I-NP
NIUA  	NIUA  	 NNP	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
suggested  	suggested  	 VBN	O
to  	to  	 TO	O
lead  	lead  	 VB	O
to  	to  	 TO	O
chronic  	chronic  	 JJ	B-NP
urticaria  	urticaria  	 NNS	I-NP
( 	( 	 -LRB-	O
CU 	CU 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
an  	an  	 DT	O
important  	important  	 JJ	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
patients 	patients 	 NNS	O
,  	,  	 ,	O
such  	such  	 JJ	O
that  	that  	 IN	O
NIUA  	NIUA  	 NNP	B-NP
may  	may  	 MD	O
therefore  	therefore  	 RB	O
precede  	precede  	 VB	O
CU 	CU 	 NNP	B-NP
.  	.  	 .	O
Our  	Our  	 PRP$	O
aim  	aim  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
verify  	verify  	 VB	O
whether  	whether  	 IN	O
these  	these  	 DT	O
entities  	entities  	 NNS	O
are  	are  	 VBP	O
related  	related  	 VBN	O
by  	by  	 IN	O
following  	following  	 VBG	O
up  	up  	 RP	O
a  	a  	 DT	O
large  	large  	 JJ	O
cohort  	cohort  	 NN	B-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
NIUA  	NIUA  	 NNP	B-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
a  	a  	 DT	O
control  	control  	 NN	B-NP
group  	group  	 NN	I-NP
over  	over  	 IN	O
a  	a  	 DT	O
long  	long  	 JJ	O
period  	period  	 NN	O
of  	of  	 IN	O
time 	time 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
study  	study  	 NN	O
comprised  	comprised  	 VBD	O
three  	three  	 CD	O
groups 	groups 	 NNS	O
:  	:  	 :	O
( 	( 	 -LRB-	O
i 	i 	 FW	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
confirmed  	confirmed  	 JJ	O
history  	history  	 NN	O
of  	of  	 IN	O
NIUA  	NIUA  	 NNP	B-NP
( 	( 	 -LRB-	O
more  	more  	 JJR	O
than  	than  	 IN	O
two  	two  	 CD	O
episodes  	episodes  	 NNS	O
with  	with  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
two  	two  	 CD	O
different  	different  	 JJ	O
NSAIDs  	NSAIDs  	 JJ	O
or  	or  	 CC	O
positive  	positive  	 JJ	B-NP
drug  	drug  	 NN	I-NP
provocation  	provocation  	 NN	I-NP
tests 	tests 	 NNS	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
( 	( 	 -LRB-	O
ii 	ii 	 LS	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
more  	more  	 JJR	O
than  	than  	 IN	O
two  	two  	 CD	O
episodes  	episodes  	 NNS	O
of  	of  	 IN	O
urticaria 	urticaria 	 CD	B-NP
/ 	/ 	 CD	I-NP
angioedema  	angioedema  	 NN	I-NP
to  	to  	 TO	O
a  	a  	 DT	O
single  	single  	 JJ	O
NSAID  	NSAID  	 NN	B-NP
with  	with  	 IN	O
good  	good  	 JJ	O
tolerance  	tolerance  	 NN	O
to  	to  	 TO	O
a  	a  	 DT	O
strong  	strong  	 JJ	O
COX-1  	COX-1  	 CD	B-NP
inhibitor  	inhibitor  	 NNS	I-NP
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
evidence  	evidence  	 NN	O
by  	by  	 IN	O
in  	in  	 IN	O
vivo  	vivo  	 JJ	B-NP
tests  	tests  	 NNS	I-NP
supporting  	supporting  	 VBG	O
specific  	specific  	 JJ	O
IgE  	IgE  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
drug  	drug  	 NN	O
( 	( 	 -LRB-	O
single  	single  	 FW	B-NP
NSAID-induced  	NSAID-induced  	 FW	I-NP
urticaria 	urticaria 	 FW	I-NP
/ 	/ 	 FW	I-NP
angioedema 	angioedema 	 FW	I-NP
,  	,  	 ,	O
SNIUA 	SNIUA 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
( 	( 	 -LRB-	O
iii 	iii 	 LS	O
)  	)  	 -RRB-	O
controls  	controls  	 VBZ	O
who  	who  	 WP	O
tolerated  	tolerated  	 VBP	O
NSAIDs 	NSAIDs 	 JJ	O
.  	.  	 .	O
All  	All  	 DT	O
cases  	cases  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
three  	three  	 CD	O
groups  	groups  	 NNS	O
were  	were  	 VBD	O
followed  	followed  	 VBN	O
up  	up  	 RP	O
over  	over  	 IN	O
a  	a  	 DT	O
period  	period  	 NN	O
of  	of  	 IN	O
12 years 	12 years 	 CD	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
190  	190  	 CD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
NIUA  	NIUA  	 NNP	B-NP
( 	( 	 -LRB-	O
64.6 	64.6 	 NNP	O
%  	%  	 NN	O
female 	female 	 NN	O
;  	;  	 :	O
mean  	mean  	 JJ	O
age  	age  	 NN	O
43.71 ± 15.82 years 	43.71 ± 15.82 years 	 NN	O
,  	,  	 ,	O
110  	110  	 CD	O
with  	with  	 IN	O
SNIUA 	SNIUA 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
152  	152  	 CD	O
controls 	controls 	 NNS	O
.  	.  	 .	O
At  	At  	 IN	O
the  	the  	 DT	O
12-year  	12-year  	 JJ	O
evaluation 	evaluation 	 NN	O
,  	,  	 ,	O
12  	12  	 CD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
NIUA  	NIUA  	 NNP	B-NP
( 	( 	 -LRB-	O
6.15 	6.15 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
had  	had  	 VBD	O
developed  	developed  	 VBN	B-NP
CU  	CU  	 NNP	I-NP
over  	over  	 IN	O
a  	a  	 DT	O
1-  	1-  	 NN	O
to  	to  	 TO	O
8-year  	8-year  	 CD	O
period 	period 	 NN	O
.  	.  	 .	O
Similar  	Similar  	 JJ	B-NP
proportions  	proportions  	 NNS	I-NP
were  	were  	 VBD	O
seen  	seen  	 VBN	O
in  	in  	 IN	O
SNIUA  	SNIUA  	 NNP	B-NP
and  	and  	 CC	O
controls 	controls 	 NNS	O
.  	.  	 .	O
Nonsteroidal  	Nonsteroidal  	 FW	B-NP
anti-inflammatory  	anti-inflammatory  	 FW	I-NP
drugs-induced  	drugs-induced  	 FW	O
urticaria 	urticaria 	 FW	B-NP
/ 	/ 	 FW	I-NP
angioedema  	angioedema  	 FW	I-NP
does  	does  	 VBZ	O
not  	not  	 RB	O
seem  	seem  	 VB	O
to  	to  	 TO	O
precede  	precede  	 VB	O
the  	the  	 DT	O
onset  	onset  	 NN	O
of  	of  	 IN	O
CU  	CU  	 NNP	B-NP
over  	over  	 IN	O
the  	the  	 DT	O
medium  	medium  	 NN	O
term 	term 	 NN	O
.  	.  	 .	O
Further  	Further  	 JJ	B-NP
research  	research  	 NN	I-NP
including  	including  	 VBG	O
a  	a  	 DT	O
longer  	longer  	 JJR	O
follow-up  	follow-up  	 NN	O
is  	is  	 VBZ	O
necessary  	necessary  	 JJ	O
to  	to  	 TO	O
verify  	verify  	 VB	O
this  	this  	 DT	O
observation 	observation 	 NN	O
.  	.  	 .	O
